Charles J. Rosser, MD, MBA, FACS
President, Nonagen Bioscience Corporation
Dr. Rosser obtained a BS degree in Biology from Fairleigh Dickinson University and an MD from Rutgers University School of Medicine (Robert Wood Johnson Medical School). Subsequently he went on to a urology residency at Wake Forest University school of Medicine and Urologic Oncology fellowship at UT MD Anderson Cancer Center. While at UT MD Anderson Cancer Center, Dr. Rosser was an American Foundation of Urologic Disease scholar. He joined the University of Florida as Assistant Professor in 2003, Associate Professor in 2008 and Professor and Chief of Urologic Oncology at M. D. Anderson Cancer Center Orlando (2009-2013). He is currently Professor, Director of Clinical and Translational Research Program and Director of Clinical Trials Office at the University of Hawaii Cancer Center, an NCI-designated cancer center. Dr. Rosser has been PI of numerous clinical trials and has received extramural funding from American Cancer Society, Department of Defense and National Cancer Institute. In addition, he has authored over 150 peer reviewed research articles. His research interests include molecular diagnostics and experimental therapeutics.
Steve Goodson, PhD
CEO, Nonagen Bioscience Corporation
Dr. Goodison obtained a BSc degree in Biochemistry from the University of Wales and a PhD in molecular biology from Oxford University in 1993 as a Wellcome Trust Scholar, and continued postdoctoral studies at Oxford University as a Wellcome Trust Fellow in the Dept. of Clinical Biochemistry. Since focusing on cancer research he joined the University of California, San Diego as Assistant Professor in 2001, was an Associate Professor at the University of Florida (2004 – 2009), and Professor and Director of the Cancer Research Institute at M. D. Anderson Cancer Center Orlando (2009-2013). He is currently Professor of Urology at the Mayo Clinic. Dr. Goodison has received several major NCI awards and published over 150 research articles. Research interests include tumor biology, gene regulation and translational studies in biomarker discovery for development of clinical diagnostic and prognostic assays.